Article citationsMore>>
L. H. Butterfield, B. Comin-Anduix, L. Vujanovic, Y. Lee, V. B. Dissette, J. Q. Yang, H. T. Vu, E. Seja, D. K. Oseguera, D. M. Potter, J. A. Glaspy, J. S. Economou and A. Ribas, “Adenovirus MART-1-Engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma,” Journal of Immunotherapy, Vol. 31, No. 3, 2008, pp. 294-309.
doi:10.1097/CJI.0b013e31816a8910
has been cited by the following article:
-
TITLE:
Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses
AUTHORS:
Kristian M. Hargadon
KEYWORDS:
Melanoma; Tumor Immunotherapy; Dendritic Cell; Tumor Antigen; T Cell; Vaccine; Adoptive Transfer
JOURNAL NAME:
Journal of Cosmetics, Dermatological Sciences and Applications,
Vol.3 No.2A,
June
20,
2013
ABSTRACT:
Melanoma is the most aggressive form
of skin cancer and accounts for the vast majority of skin cancer-related
deaths. Its ability to metastasize quickly, often before diagnosis, makes this
cancer difficult to treat with traditional therapies. The identification of
anti-melanoma immune responses in patients and the discovery of tumor antigens
targeted by these immune responses have paved the way for immunotherapy as a
novel approach to treating this cancer. In this review, the major
immunotherapies targeting these melanoma tumor antigens are discussed. The
advantages and limitations of peptide-, protein-, and gene-based vaccination
maneuvers and adoptive cell transfer therapies are emphasized. Recent insights
into melanoma immune evasion strategies are also highlighted, with particular
focus on how our increasing knowledge of tumor/immune cell interactions is
driving the development of novel immunotherapeutic strategies for the treatment
of melanoma.
Related Articles:
-
Anestakis Doxakis, Argyraki Maria, Petanidis Savvas, Iakovidou-Kritsi Zafiroula
-
Casimir Komenan
-
Mudassar Iqbal, Anima Langer, Afroz Alam
-
Moawwad E. A. El-Mikkawy
-
Zheng Yuan